PGEN vs TEM: fair value comparison
Precigen, Inc. and Tempus AI, Inc. · Updated 2026-10-19
PGEN's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. TEM has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PGEN currently ranks higher by quality score.
| PGEN | TEM | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $6.38 | $64.72 |
| 12-month range | $3.10–$8.56 | $41.55–$91.58 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #159 of 301 Healthcare | #161 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | High | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | — | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: PGEN fair value analysis · TEM fair value analysis